#USA #San Sebastián #Viralgen #Elaaj Bio #CDKL5 Disorder

Viralgen Partners with Elaaj Bio to Transform CDKL5 Therapy

In a significant advancement for pediatric neurological treatment, Viralgen, a prominent contract development and manufacturing organization, has joined forces with Elaaj Bio to propel their investigational gene therapy for CDKL5 Deficiency Disorder (CDD). This partnership combines expertise in developing therapies critical for addressing rare pediatric diseases, which often have limited treatment options.

Understanding CDKL5 Deficiency Disorder

CDKL5 Deficiency Disorder is a rare genetic condition primarily affecting young children. Caused by mutations in the CDKL5 gene, the disorder is characterized by severe developmental delays and early onset seizures, which can be devastating not only to the affected children but also to their families. Given the rare nature of CDD, there is an urgent need for innovative therapies that tackle the underlying genetic causes of the disorder.

The Role of Viralgen

Based in San Sebastián, Spain, Viralgen specializes in recombinant adeno-associated virus (rAAV) gene therapies. The company has established itself as a leader in this space since its inception in 2017 as a subsidiary of AskBio, Inc., and now part of Bayer AG. Viralgen’s expertise will play a critical role in scaling the manufacturing processes necessary for the gene therapy involving AAV vectors, which are essential for delivering genetic material into cells effectively. The company’s proprietary Pro10™ cell line and Aava™ manufacturing platform is designed to yield high quantities of rAAV, facilitating the large-scale production needed for clinical trials.

As part of the collaboration, Viralgen will undertake vital tasks including process development, optimization, and quality control, ensuring that the gene therapy can be produced at a scale suitable for human trials. Previously conducted testing has confirmed that the manufacturing approach is technically feasible, and the teams are now focused on scaling up the production process.

Elaaj Bio and its Mission

Elaaj Bio operates as a branch of the Loulou Foundation, a UK-based non-profit focused entirely on CDD research. The foundation funds a range of projects aimed at furthering the understanding of the condition and developing new therapeutics. They have established extensive collaborations with researchers in both the US and Europe to push forward 31 separate research projects dedicated to finding treatments for this challenging disorder.

Russ Addis, leading the pipeline strategy at the Loulou Foundation, emphasized the importance of their mission-driven approach. He stated, "Our focus is entirely on finding treatments for CDD, and we are hopeful that our collaboration with Viralgen will lead to effective solutions that address the root causes of this disorder."

Looking Ahead

Both organizations are setting their sights on initiating the first clinical trial for the gene therapy, named ELJ-101, in early 2027. Preparing for clinical development requires not only solid manufacturing processes but also rigorous testing protocols to ensure safety and efficacy. The continued commitment from both Viralgen and Elaaj Bio signals a positive trajectory toward something that could greatly benefit children suffering from this debilitating condition.

In conclusion, the partnership between Viralgen and Elaaj Bio epitomizes the collaborative spirit essential for advancing medical innovation. By uniting manufacturing and clinical development expertise, they are taking significant steps toward providing hope for families affected by CDKL5 Deficiency Disorder.